BlackRock Institutional Trust’s Neurogene NGNE Stock Holding History

BlackRock Institutional Trust’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.1M	Buy	15,434 +4,430	+40%	+$1.19M	﹤0.01%	2721
2016 Q3	$2.94M	Buy	11,004 +1,021	+10%	+$206K	﹤0.01%	2913
2016 Q2	$1.32M	Hold	9,983	–	–	﹤0.01%	3208
2016 Q1	$1.76M	Buy	9,983 +1,250	+14%	+$243K	﹤0.01%	3090
2015 Q4	$2.18M	Buy	8,733 +1,265	+17%	+$333K	﹤0.01%	3082
2015 Q3	$2.1M	Buy	+7,468	New	+$1.72M	﹤0.01%	3100
2015 Q2	–	Sell	-55	Closed	-$9K	–	3941
2015 Q1	$9K	Sell	55 -78	-59%	-$15.8K	﹤0.01%	3822
2014 Q4	$20K	Hold	133	–	–	﹤0.01%	3831
2014 Q3	$18K	Buy	+133	New	+$20.3K	﹤0.01%	3773

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Institutional Trust's NGNE Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Neurogene (NGNE) stake by 40% in Q4 2016, buying an estimated $1.19M and bringing the position to 15,434 shares worth $5.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

BlackRock Institutional Trust first reported a position in NGNE in Q3 2014 and has held it in 9 quarters since. 49 funds tracked by Wall St. Rank hold NGNE as of Q4 2016.

BlackRock Institutional Trust held 15,434 shares of Neurogene worth $5.1M as of Q4 2016.
BlackRock Institutional Trust bought 4,430 Neurogene shares in Q4 2016, an estimated $1.19M.
Neurogene made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2721 holding.
BlackRock Institutional Trust first reported a position in Neurogene in Q3 2014 and has held it in 9 quarters since.
49 funds tracked by Wall St. Rank held Neurogene as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.